Autolus

Christian Itin, Ph.D., CEO
London, United Kingdom
(NASDAQ: AUTL)

Virtual Presentation
Autolus is focused on the development of precisely targeted, controlled, and highly active T cell therapies that are designed to offer cancer patients substantial benefits over existing standard of care. Autolus is a leader in T cell programming technologies and believes its leadership will provide a competitive advantage as it looks to develop future generations of T cell therapies targeting both hematological cancers and solid tumors.
www.autolus.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions